Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution

Cancer Research

Volumn 67, Issue 14, 2007, Pages 6965-6972

  Takenaka, Kazumasa ^a   Morgan, Jessica A ^a   Scheffer, George L ^b,c   Adachi, Masashi ^a   Stewart, Clinton F ^a   Sun, Daxi ^a   Leggas, Markos ^a   Ejendal, Karin F K ^d   Hrycyna, Christine A ^d   Schuetz, John D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; BREAST CANCER RESISTANCE PROTEIN; CLADRIBINE; IODINE 125; MULTIDRUG RESISTANCE PROTEIN 4; PRAZOSIN; PURINE DERIVATIVE; PUROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; SPLEEN CELL; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PURINES; SPLEEN; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION;

EID: 34547114499     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4720     Document Type: Article

References (52)

1. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000;113:2011-21.
2. Doyle LA, Ross DD. Multidrugresis tance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
3. Maher JM, Slitt AL, Cherrington NJ, Cheng X, Klaassen CD. Tissue distribution and hepatic and renal ontogeny of the multidrugresis tance-associated protein (Mrp) family in mice. Drug Metab Dispos 2005;33:947-55.
4. Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Abcg2/Abcg2) in rats and mice. Biochem Biophys Res Commun 2005;326:181-7.
5. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-51.
6. Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004;24:7612-21.
7. Norris MD, Smith J, Tanabe K, et al. Expression of multidrugtransporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther 2005;4:547-53.
8. Yang C-H, Schneider E, Kuo M-L, Volk EL, Rocchi E, Chen Y-C. ABCG2/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 2000;60:831-7.
9. Volk EL, Rohde K, Rhee M, et al. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 2000;60:3514-21.
10. Pauwels R, Balzarini J, Schols D, et al. Phosphonylmethoxyethyl purine derivatives, a new class of antihuman immunodeficiency virus agents. Antimicrob Agents Chemother 1988;32:1025-30.
11. Zhou S, Morris JJ, Barnes Y, et al. Abcg21 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A 2002;99:12339-44.
12. Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma 2003;44:391-409.
13. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005;115:110-7.
14. Wierdl M, Wall A, Morton CL, et al. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drugresis tance. Mol Pharmacol 2003;64:279-88.
15. Lee JK, Ryu MH, Byun JA. Immunotoxic effect of β-chlorolactic acid on murine splenocyte and peritoneal macrophage function in vitro. Toxicology 2005;210:175-87.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
17. Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Functional expression of human P-glycoprotein from plasmids usingvaccinia virus-bacteriophage T7 RNA polymerase system. Methods Enzymol 1998;292:456-73.
18. Adachi M, Sampath J, Lan L-B, et al. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J Biol Chem 2002;277:38998-9004.
19. Hatse S, De Clercq E, Balzarini J. Enhanced 9-(2-phosphonylmethoxyethyl) adenine secretion by a specific, indomethacin-sensitive efflux pump in a mutant 9-(2-phosphonylmethoxyethyl)adenine-resistant human erythroleukemia K562 cell line. Mol Pharmacol 1998;54:907-17.
20. Chu XY, Strauss JR, Mariano MA, et al. Characterization of mice lackingthe multidrugresis tance protein MRP2 (ABCC2). J Pharmacol Exp Ther 2006;317:579-89.
21. Naesens L, Balzarini J, Bischofberger N, De Clercq E. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2- phosphonylmethoxyethyl) adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother 1996;40:22-8.
22. Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 2005;312:44-52.
23. de la Luna S, Ortin J. pac gene as efficient dominant marker and reporter gene in mammalian cells. Methods Enzymol 1992;216:376-85.
24. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A 1980;77:6865-9.
25. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividinghum an lymphocytes. J Clin Invest 1985;75:377-83.
26. Ejendal KFK, Hrycyna CA. Differential sensitivities of the human ATP-bindingcasset te transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol Pharmacol 2005;67:902-11.
27. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001;276:33747-54. Epub 2001 Jul 10.
28. Lee K, Klein-Szanto AJP, Kruh GD. Analysis of the MRP4 drugresis tance profile in transfected NIH3T3 cells. J Natl Cancer Inst 2000;92:1934-40.
29. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-34.
30. de Wolf CJ, Yamaguchi H, van der Heijden I, et al. cGMP transport by vesicles from human and mouse erythrocytes. FEBS J 2007;274:439-50.
31. De Clercq E. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem Pharmacol 1991;42:963-72.
32. Balzarini J, Naesens L, Herdewijn P, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl) adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A 1989;86:332-6.
33. Gangemi JD, Cozens RM, De Clercq E, Balzarini J, Hochkeppel HK. 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob Agents Chemother 1989;33:1864-8.
34. Yokota T, Mochizuki S, Konno K, Mori S, Shigeta S, De Clercq E. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob Agents Chemother 1991;35:394-7.
35. Murono S, Raab-Traub N, Pagano JS. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res 2001;61:7857-7.
36. Hatse S, Naesens L, Deg r eve B, et al. Potent antitumor activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine in choriocarcinoma-bearing rats. Int J Cancer 1998;76:595-600.
37. Qaqish RB, Mattes KA, Ritchie DJ. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Ther 2003;25:3084-99.
38. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003;16:569-96.
39. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005;43:937-43.
40. Yang H, Westland CE, Delaney WE 4th, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-73.
41. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
42. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999;282:2305-12.
43. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000;11:383-93.
44. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 2001;299:567-74.
45. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analogdrug s by the human multidrugresis tance proteins MRP4 and MRP5. Mol Pharmacol 2003;63:1094-103.
46. Servais A, Lechat P, Zahr N, et al. Tubular transporters and clearance of adefovir. Eur J Pharmacol 2006;540:168-74.
47. Alessi-Severini S, Gati WP, Belch AR, Paterson AR. Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Leukemia 1995;9:1674-9.
48. Wright AM, Gati WP, Paterson AR. Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. Leukemia 2000;14:52-60.
49. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A 1997;94:10594-9.
50. Shapiro AB, Ling V. Positively cooperative sites for drugtransport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997;250:130-7.
51. Van Aubel RAMH, Smeets PHE, van den Heuvel JJMW, Russel FGM. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate bindingsites. Am J Physiol Renal Physiol 2005;288:F327-33.
52. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 1999;259:841-50.